Targeting cytokines beyond tumor necrosis factor-α and interleukin-1 in rheumatoid arthritis

Current Pain and Headache Reports

Volumn 9, Issue 6, 2005, Pages 405-411

  McInnes, Iain B ^a   Gracie, J Alastair ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN G1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DISEASE MODEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; RANDOMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS;

EID: 28944454010     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-005-0020-9     Document Type: Review

References (61)

1. Taylor PC, Williams RO, Maini RN: Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 2001, 13:611-616.
2. Klareskog L, van der Heijde D, de Jager JP, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004, 363:675-681.
3. Nishimoto N, Kishimoto T, Yoshizaki K: Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000, 59:21-27.
4. Alonzi T, Fattori E, Lazzaro D, et al.: Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998, 187:461-468.
5. Takagi N, Mihara M, Moriya Y, et al.: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998, 41:2117-2121.
6. Mihara M, Kotoh M, Nishimoto N, et al.: Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 2001, 98:319-326.
7. Choy EH, Isenberg DA, Garrood T, et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46:3143-3150.
8. Nakahara H, Song J, Sugimoto M, et al.: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
9. Nishimoto N, Yoshizaki K, Miyasaka N, et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761-1769.
10. Yokota S: Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003, 15:581-586.
11. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
12. Miossec P: Are T cells in rheumatoid synovium aggressors or bystanders? Curr Opin Rheumatol 2000, 12:181-185.
13. Morita Y, Yamamura M, Nishida K, et al.: Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 1998, 41:306-314.
14. Hessian PA, Highton J, Kean A, et al.: Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 2003, 48:334-338.
15. Gracie JA, Forsey RJ, Chan WL, et al.: A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999, 104:1393-1401.
16. Hess H, Gately MK, Rude E, et al.: High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant. Eur J Immunol 1996, 26:187-191.
17. Leung BP, McInnes IB, Esfandiari E, et al.: Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol 2000, 164:6495-6502.
18. Malfait AM, Butler DM, Presky DH, et al.: Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998, 111:377-383.
19. Joosten LA, Lubberts E, Helsen MM, van den Berg WB: Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol 1997, 159:4094-4102.
20. Butler DM, Malfait AM, Maini RN, et al.: Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol 1999, 29:2205-2212.
21. Joosten LA, Heuvelmans-Jacobs M, Lubberts E, et al.: Local interleukin-12 gene transfer promotes conversion of an acute arthritis to a chronic destructive arthritis. Arthritis Rheum 2002, 46:1379-1389.
22. Finnegan A, Grusby MJ, Kaplan CD, et al.: IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002, 169:3345-3352.
23. Frucht DM, Aringer M, Galon J, et al.: Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol 2000, 164:4659-4664.
24. Murphy CA, Langrish CL, Chen Y, et al.: Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
25. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S: Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001, 30:203-207.
26. Grabstein KH, Eisenman J, Shanebeck K, et al.: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994, 264:965-968.
27. Waldmann TA, Tagaya Y: The multifaceted regulation of interleukin-15 expression and the role of this cytokine in nk cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999, 17:19-49.
28. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
29. Giri JG, Kumaki S, Ahdieh M, et al.: Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. Embo J 1995, 14:3654-3663.
30. Waldmann T, Tagaya Y, Bamford R: Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998, 16:205-226.
31. McInnes IB, Gracie JA, Harnett M, et al.: New strategies to control inflammatory synovitis: interleukin 15 and beyond. Ann Rheum Dis 2003, 62(Suppl 2):51-54.
32. McInnes IB, Leung BP, Sturrock RD, et al.: Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997, 3:189-195.
33. Gonzalez-Alvaro I, Ortiz AM, Garcia-Vicuna R, et al.: Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. Clin Exp Rheumatol 2003, 21:639-642.
34. Smolewska E, Brozik H, Smolewski P, et al.: Apoptosis of peripheral blood lymphocytes in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2003, 62:761-763.
35. McInnes IB, Leung BF, Liew FY: Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res 2000, 2:374-378.
36. Cho ML, Yoon CH, Hwang SY, et al.: Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum 2004, 50:776-784.
37. Groh V, Bruhl A, El-Gabalawy H, et al.: Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A 2003, 100:9452-9457.
38. Wang CR, Liu MF: Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 2003, 132:371-378.
39. Ruchatz H, Leung BP, Wei XQ, et al.: Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998, 160:5654-5660.
40. Kim YS, Maslinski W, Zheng XX, et al.: Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol 1998, 160:5742-5748.
41. Ferrari-Lacraz S, Zheng YX, Kim YS, et al.: An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001, 167:3478-3485.
42. Nakamura K, Okamura H, Wada M, et al.: Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989, 57:590-595.
43. Gracie JA, Robertson SE, McInnes IB: Interleukin-18. J Leukoc Biol 2003, 73:213-224.
44. Ghayur T, Banerjee S, Hugunin M, et al.: Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997, 386:619-623.
45. Gu Y, Kuida K, Tsutsui H, et al.: Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997, 275:206-209.
46. Sugawara S, Uehara A, Nochi T, et al.: Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 2001, 167:6568-6575.
47. Dinarello CA, Fantuzzi G: Interleukin-18 and host defense against infection. J Infect Dis 2003, 187(Suppl 2):S370-384.
48. Mehta VB, Hart J, Wewers MD: ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem 2001, 276:3820-3826.
49. Torigoe K, Ushio S, Okura T, et al.: Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997, 272:25737-25742.
50. Born TL, Thomassen E, Bird TA, Sims JE: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998, 273:29445-29450.
51. Adachi O, Kawai T, Takeda K, et al.: Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9:143-150.
52. Novick D, Kim SH, Fantuzzi G, et al.: Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10:127-136.
53. Pan G, Risser P, Mao W, et al.: IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL,1Rrp. Cytokine 2001, 13:1-7.
54. Yamamura M, Kawashima M, Taniai M, et al.: Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 2001, 44:275-285.
55. Kawashima M, Miossec P: Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum 2003, 48:631-637.
56. Lubberts E, van den Berg WB: Potential of modulatory cytokines in the rheumatoid arthritis process. Drug News Perspect 2001, 14:517-522.
57. Leung BP, Culshaw S, Gracie JA, et al.: A role for IL-18 in neutrophil activation. J Immunol 2001, 167:2879-2886.
58. Horwood NJ, Udagawa N, Elliott J, et al.: Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 1998, 101:595-603.
59. Wei XQ, Leung BP, Arthur HM, et al.: Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001, 166:517-521.
60. Plater-Zyberk C, Joosten LA, Helsen MM, et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001, 108:1825-1832.
61. Smeets RL, Van De Loo FA, Arntz OJ, et al.: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 2003, 10:1004-1011.